Publications by authors named "X Leleu"

Claim this Profile
P
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial.
Françoise Kraeber-Bodéré, Bastien Jamet, Sonja Zweegman, Aurore Perrot, Cyrille Hulin, Xavier Leleu

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Xavier Leleu

Lancet Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.
Thomas Chalopin, Elise Cellerin, Hélène Demarquette, Andréa Pieragostini, Cécile Sonntag, Xavier Leleu

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot, Xavier Leleu

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
Anaïs Schavgoulidze, Aurore Perrot, Xavier Leleu, Titouan Cazaubiel, Marie-Lorraine Chretien

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis